Related Experiment Video
Updated: Apr 8, 2026
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Establishment and Characterization of Two Novel Human Pancreatic Carcinoma Cell Lines
Katsuhisa Hirano1, Tomoyuki Okumura2, Yutaka Shimada1
1Department of Surgery and Science, University of Toyama. Sugitani, Toyama City, Toyama, Japan.
Background:
Pancreatic carcinoma (PC) is among the most lethal types of carcinomas worldwide. We aimed to establish well-defined PC cell lines in order to determine their resistance to chemotherapy.
Materials And Methods:
Cells cultured from the tumors of two patients were analyzed for xenograft formation, V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) and TP53 mutations, chemosensitivity, and mRNAs encoding rate-limiting enzymes that metabolize anticancer drugs.
Results:
The TYPK-1 and TYPK-2 cell lines were established from the lymph node of a locally advanced PC and from the ascites of a multi-metastatic and multi-chemoresistant PC, respectively. Each cell line generated tumors in nude mice. KRAS and TP53 mutations were detected in TYPK-1 but not TYPK-2 cells. TYPK-1 cells were resistant to gemcitabine, and TYPK-2 cells were resistant to oxaliplatin. The gemcitabine sensitivity of each cell line correlated with the expression of mRNAs encoding DCK and SLCAC29A1.
Conclusion:
TYPK-1 and TYPK-2 cells may contribute to investigations of resistance to anticancer drugs.
